MX2008001606A - Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico. - Google Patents

Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.

Info

Publication number
MX2008001606A
MX2008001606A MX2008001606A MX2008001606A MX2008001606A MX 2008001606 A MX2008001606 A MX 2008001606A MX 2008001606 A MX2008001606 A MX 2008001606A MX 2008001606 A MX2008001606 A MX 2008001606A MX 2008001606 A MX2008001606 A MX 2008001606A
Authority
MX
Mexico
Prior art keywords
sub
receptor antagonists
glutamate receptor
metabotropic glutamate
substituted piperazines
Prior art date
Application number
MX2008001606A
Other languages
English (en)
Inventor
Abdelmalik Slassi
Louise Edwards
Methvin Isaac
Tao Xin
Donald Mcleod
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2008001606A publication Critical patent/MX2008001606A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La invencion se refiere a compuestos de la formula I o sus sales o solvatos farmaceuticamente aceptables, en donde: Ar1, Ar2, Hy, L, R1, m y n son como se define en la descripcion. La invencion tambien incluye composiciones farmaceuticas y usos de, y procedimientos para hacer los compuestos, asi como metodos de tratamiento medico de trastornos mediados por mGluR5.
MX2008001606A 2005-08-15 2006-08-04 Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico. MX2008001606A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70794605P 2005-08-15 2005-08-15
PCT/US2006/030392 WO2007021573A1 (en) 2005-08-15 2006-08-04 Substituted piperazines as metabotropic glutamate receptor antagonists

Publications (1)

Publication Number Publication Date
MX2008001606A true MX2008001606A (es) 2008-04-14

Family

ID=37451198

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008001606A MX2008001606A (es) 2005-08-15 2006-08-04 Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.

Country Status (16)

Country Link
US (2) US20080312246A1 (es)
EP (1) EP1919901A1 (es)
JP (1) JP2009504734A (es)
KR (1) KR20080057224A (es)
CN (1) CN101287722A (es)
AR (1) AR057728A1 (es)
AU (1) AU2006280231A1 (es)
BR (1) BRPI0615163A2 (es)
CA (1) CA2616307A1 (es)
IL (1) IL188806A0 (es)
MX (1) MX2008001606A (es)
NO (1) NO20080670L (es)
TW (1) TW200800946A (es)
UY (1) UY29735A1 (es)
WO (1) WO2007021573A1 (es)
ZA (1) ZA200801035B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0711521D0 (en) * 2007-06-14 2007-07-25 Glaxo Group Ltd Novel compounds
JP2011515359A (ja) * 2008-03-18 2011-05-19 グラクソ グループ リミテッド 治療用トリアゾールアミド誘導体
US8536169B2 (en) 2008-06-05 2013-09-17 Glaxo Group Limited Compounds
WO2009147188A1 (en) * 2008-06-05 2009-12-10 Glaxo Group Limited Benzpyrazol derivatives as inhibitors of pi3 kinases
ES2383246T3 (es) * 2008-06-05 2012-06-19 Glaxo Group Limited 4-amino-indazoles
WO2010102958A1 (en) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
BRPI1016219B8 (pt) 2009-04-30 2021-05-25 Glaxo Group Ltd composto indazol substituído com oxazol, e, composição farmacêutica
GB2497476B (en) 2010-09-06 2018-01-10 Guangzhou Inst Biomed & Health Amide Compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) * 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
CN113087669B (zh) * 2019-12-23 2023-11-17 南京药石科技股份有限公司 一种4-氰基-5-溴嘧啶的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL81669A (en) * 1986-02-27 1990-11-29 Duphar Int Res Aryl-substituted(n-piperidinyl)methyl-and(n-piperazinyl)-methylazoles,their preparation and pharmaceutical compositions containing them
US5681956A (en) * 1990-12-28 1997-10-28 Neurogen Corporation 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
US6313127B1 (en) * 1996-02-02 2001-11-06 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
WO2003093236A1 (en) * 2002-05-02 2003-11-13 Euro-Celtique, S.A. 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor
MXPA05001592A (es) * 2002-08-09 2005-05-05 Astrazeneca Ab Oxadiazoles como moduladores de receptor-5 de glutamato metabotropico.
EP1590329A1 (fr) * 2003-01-28 2005-11-02 Aventis Pharma S.A. Produits n-aryl-heteroaromatiques, compositions les contenant et utilisation
PE20050226A1 (es) * 2003-06-04 2005-05-18 Aventis Pharma Sa Productos aril-heteroaromaticos y composiciones que los contienen
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2005077373A2 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)

Also Published As

Publication number Publication date
NO20080670L (no) 2008-04-01
TW200800946A (en) 2008-01-01
UY29735A1 (es) 2007-02-28
US20080312246A1 (en) 2008-12-18
WO2007021573A1 (en) 2007-02-22
BRPI0615163A2 (pt) 2016-09-13
EP1919901A1 (en) 2008-05-14
CN101287722A (zh) 2008-10-15
AR057728A1 (es) 2007-12-12
KR20080057224A (ko) 2008-06-24
IL188806A0 (en) 2008-08-07
JP2009504734A (ja) 2009-02-05
US20070037820A1 (en) 2007-02-15
CA2616307A1 (en) 2007-02-22
ZA200801035B (en) 2008-12-31
AU2006280231A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
SG146657A1 (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
TW200630361A (en) Integrin antagonists useful as anticancer agents
IL177291A0 (en) Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2006038006A3 (en) 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
HK1120725A1 (en) Tetrahydro-beta-carbolin-sulfonamide derivatives as 5-ht6ligands
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
TW200720260A (en) Prokineticin 1 receptor antagonists
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
TW200716566A (en) Prokineticin 2 receptor antagonists
TW200800943A (en) Indane derivatives as MCH receptor antagonists
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
TW200637817A (en) 5-aminoindole derivatives
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
MX2008001608A (es) Piperazinas acetilenicas como antagonistas de receptor de glutamato metabotropico.
MX2008001607A (es) Piperazinas biciclicas como antagonistas del receptor de glutamato metabotropico.
RS20050892A (en) Imidazole derivatives as glutamate receptor antagonists
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
MX2009000762A (es) 4-arilalcoximetil-4-fenil piperidinas y su uso como antagonistas del receptor de neuroquinina para el tratamiento de trastornos del sistema nervioso central.
PL1732902T3 (pl) Pochodne nukleozydów i ich terapeutyczne zastosowanie
MY148488A (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2004080411A3 (en) Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
MXPA06002870A (es) Derivados de azetidina disubstituidos para usarse como antagonistas del receptor ccr-3 en el tratamiento de enfermedades inflamatorias y alergicas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal